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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idIn some respects, the Arabian Peninsula stands at the cross-
roads of human migration, through tourism and economic
migration. It is thus logical that this may generate a melting pot
of human infections, particularly those caused by antibiotic-
resistant bacteria. Many of the migrant workers come from
countries where antibiotic distribution is poorly managed and they
often carry bacteria laden with resistance genes. In addition, this
area of the world is a hub of international trade, with large
numbers of transient visitors.1 Although this region often has
state-of-the-art medical treatment facilities, the support infra-
structure is less robust, as there is often a lack of systematic
nationwide surveillance programmes with publicly available data,
a variety of different diagnostic guidelines, and the common
availability of over-the-counter drugs.2,3 It is also virtually
unknown what impact the agricultural use of antibiotics has
had on the development of resistance in clinical bacteria in the
area, either in local farming practices or from the huge quantities of
agricultural products that are imported.2–6 All these factors have
led this region to be increasingly recognized as a major contributor
to the global epidemiology of antibiotic resistance.
Countries within the Peninsula have recently been shown to be
sources of drug-resistant infections. A particular example is the
emergence and spread of carbapenem-resistant Enterobacteria-
ceae.7,8 Carbapenems had been viewed as the ‘last resort’ for the
treatment of Gram-negative bacteria, so the impact of resistance to
these has been devastating. The reintroduction of colistin did, for a
while, ameliorate the impact of these challenging bacteria, and this
became the new drug of ‘last resort’. So the emergence of colistin
resistance has been catastrophic and the ‘last resort’ has now been
overcome!
Colistin resistance has been reported around the world and has
often been manifested by the mcr-1 gene. However, it had not, until
recently, been found in bacteria isolated in the Arabian Peninsula.
Sonnevend et al. showed that this situation has changed;9 the
authors reported the presence of the mcr-1 gene in four strains of
Escherichia coli isolated from Saudi Arabia, Bahrain, and the United
Arab Emirates from 75 colistin-resistant isolates collected over a 3-
year period from 2012 to 2015. A single discovery of this gene
would have been serious enough, but to have identiﬁed this gene
with such a geographic spread suggests that mcr-1 has established
itself within the clinically important bacterial population. Inter-
estingly the authors noted that the gene was present in four
distinct multilocus sequence typing (MLST) types, so this was not
the result of direct spread. Rather they noted that in three cases thehttp://dx.doi.org/10.1016/j.ijid.2016.08.001
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).gene was carried on an IncI2 type plasmid, whereas in the fourth,
from Saudi Arabia, it was carried on a 240-kb IncHI2 plasmid. In
each case, the mcr-1 gene was located in bacteria that were
resistant to many other antibiotics and biocides, which suggests
that the use of antibiotics other than colistin could preserve these
colistin resistance genes within the clinical population. In one IncI2
type plasmid, there was direct linkage to the blaCTX-M-64 gene,
suggesting that the use of cephalosporins could promote the
spread of the host plasmid and the mcr-1 gene. However, it is the
240-kb IncHI2 plasmid that carries 13 other resistance genes
besides mcr-1 that is of particular concern. Although the plasmid
does not carry a carbapenem resistance gene, the host strain
carries the blaNDM-1 gene, conferring the metallo-b-lactamase
responsible for widespread carbapenem resistance. So, in this case,
the clinical use of carbapenems will preserve the colistin resistance
genes within the strain.
The blaNDM–1 and mcr-1 genes migrate to the same plasmid. The
240-kb IncHI2 plasmid looks like a prime candidate. This could
cause massive problems for the region, with treatment failures and
an inability to provide a positive resolution for severe Gram-
negative infections. From the medical viewpoint, what should be
the next step? It is universally considered that the best response to
severe resistance problems is rigorous surveillance and that a
culture of individual and routine diagnostic tests is rigidly
enforced. This would be backed by a robust support infrastructure
of systematic nationwide and region-wide surveillance pro-
grammes providing publicly available data, regional acceptance
of a common set of diagnostic guidelines, and the resolve to enforce
a complete ban on the availability of over-the-counter antibio-
tics.10
The article by Sonnevend et al. has highlighted that, in terms of
the ability to control severe Gram-negative infections, the clinical
profession of the region is standing at the edge of a precipice
overlooking a prescribing abyss.9 Good practice, both in surveil-
lance and prescribing, could allow a retreat from the edge. Failure
to understand the enormity of the problem of colistin resistance
will control the long-term ability to treat serious infections and
push future prescribing options over the edge into the abyss.
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